Compare Adaptive Biotechnologies Corp (ADPT) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lennar Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Lennar Corporation trades at $83.28 (market cap $20.84B). The key difference: Lennar Corporation is far larger — about 6.3× Adaptive Biotechnologies Corp's market cap, and Lennar Corporation pays a 2.31% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LEN | |
|---|---|---|
Market Cap | $3.33B | $20.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $142.40 |
52-Week Low | $10.24 | $82.30 |
Enterprise Value | $3.19B | $24.72B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Lennar (LEN) trades at $86.74, down 1.67% on the day, with a bearish technical signal despite appearing undervalued on key metrics (P/E 13.83, P/S 0.67). Recent earnings have missed expectations, with Q2 2026 EPS expected at 1.32. The company faces margin pressure as it prioritizes sales volume over price, cutting average home prices to 2017 levels to boost affordability amid high mortgage rates.
While Lennar's valuation appears attractive and analyst consensus leans bullish (46% buy ratings), near-term risks include persistent housing affordability challenges, declining profit margins, and negative cash flow trends. Execution on margin recovery through cost discipline and faster cycle times will be crucial for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
